Infectious Diseases Unit I, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Center for Infection Research Deutsches Zentrum für Infektionsforschung (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
Front Immunol. 2023 May 5;14:1182504. doi: 10.3389/fimmu.2023.1182504. eCollection 2023.
INTRODUCTION: The nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC). METHODS: Here, we comprehensively assessed the breadth and specificity of the NSP12-specific T-cell response after T-cell expansion with 185 overlapping 15-mer peptides covering the entire SARS-CoV-2 NSP12 at single-peptide resolution in a cohort of 27 coronavirus disease 2019 (COVID-19) patients. Samples of nine uninfected seronegative individuals, as well as five pre-pandemic controls, were also examined to assess potential cross-reactivity with CCCs. RESULTS: Surprisingly, there was a comparable breadth of individual NSP12 peptide-specific CD4 T-cell responses between COVID-19 patients (mean: 12.82 responses; range: 0-25) and seronegative controls including pre-pandemic samples (mean: 12.71 responses; range: 0-21). However, the NSP12-specific T-cell responses detected in acute COVID-19 patients were on average of a higher magnitude. The most frequently detected CD4 T-cell peptide specificities in COVID-19 patients were aa236-250 (37%) and aa246-260 (44%), whereas the peptide specificities aa686-700 (50%) and aa741-755 (36%), were the most frequently detected in seronegative controls. In CCC-specific peptide-expanded T-cell cultures of seronegative individuals, the corresponding SARS-CoV-2 NSP12 peptide specificities also elicited responses . However, the NSP12 peptide-specific CD4 T-cell response repertoire only partially overlapped in patients analyzed longitudinally before and after a SARS-CoV-2 infection. DISCUSSION: The results of the current study indicate the presence of pre-primed, cross-reactive CCC-specific T-cell responses targeting conserved regions of SARS-CoV-2, but they also underline the complexity of the analysis and the limited understanding of the role of the SARS-CoV-2 specific T-cell response and cross-reactivity with the CCCs.
简介:严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)的非结构蛋白 12(NSP12)与普通感冒冠状病毒(CCC)具有很高的序列同一性。
方法:在这里,我们通过在 27 名 COVID-19 患者中以单个肽分辨率用 185 个重叠的 15 肽全面评估了在 T 细胞扩增后针对 SARS-CoV-2 NSP12 的 NSP12 特异性 T 细胞反应的广度和特异性,这些肽涵盖了 SARS-CoV-2 NSP12 的整个区域。还检查了九名未感染的血清阴性个体以及五名大流行前对照的样本,以评估与 CCC 的潜在交叉反应性。
结果:令人惊讶的是,COVID-19 患者(平均:12.82 种反应;范围:0-25)和血清阴性对照(包括大流行前样本)之间的个体 NSP12 肽特异性 CD4 T 细胞反应的广度相当(平均:12.71 种反应;范围:0-21)。然而,急性 COVID-19 患者中检测到的 NSP12 特异性 T 细胞反应的平均幅度更高。COVID-19 患者中最常检测到的 CD4 T 细胞肽特异性是 aa236-250(37%)和 aa246-260(44%),而在血清阴性对照中最常检测到的肽特异性是 aa686-700(50%)和 aa741-755(36%)。在血清阴性个体的 CCC 特异性肽扩增 T 细胞培养物中,相应的 SARS-CoV-2 NSP12 肽特异性也引起了反应。然而,在 SARS-CoV-2 感染前后进行纵向分析的患者中,NSP12 肽特异性 CD4 T 细胞反应谱仅部分重叠。
讨论:本研究结果表明存在针对 SARS-CoV-2 保守区域的预形成、交叉反应性 CCC 特异性 T 细胞反应,但它们也强调了分析的复杂性以及对 SARS-CoV-2 特异性 T 细胞反应和与 CCC 交叉反应性的作用的有限理解。
Cell Rep Med. 2023-6-20
Vaccines (Basel). 2023-8-23
J Clin Invest. 2023-1-3
Microbiol Spectr. 2022-12-21
Molecules. 2022-11-10
Nucleic Acids Res. 2023-1-6